Safety of Polyphenon E in Multiple Sclerosis Pilot Study
Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
This study is an open label 6 month study. All subjects will be treated with Polyphenon E
(400 mg EGCG twice a day) for six months. The main outcome of this pilot phase will be
safety. Secondary outcomes are the change in NAA levels over 6 months as measured by
MR-spectroscopy. NAA levels are a marker of neuronal function. We think that Polyphenon E
will protect neurons and thus increase NAA levels.
Phase:
Phase 1
Details
Lead Sponsor:
Louisiana State University Health Sciences Center in New Orleans
Collaborator:
National Center for Complementary and Integrative Health (NCCIH)